JP2005516967A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516967A5
JP2005516967A5 JP2003559508A JP2003559508A JP2005516967A5 JP 2005516967 A5 JP2005516967 A5 JP 2005516967A5 JP 2003559508 A JP2003559508 A JP 2003559508A JP 2003559508 A JP2003559508 A JP 2003559508A JP 2005516967 A5 JP2005516967 A5 JP 2005516967A5
Authority
JP
Japan
Prior art keywords
secretase inhibitor
inhibitor according
manufacture
amyloid
secretase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003559508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516967A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/000504 external-priority patent/WO2003059346A1/en
Publication of JP2005516967A publication Critical patent/JP2005516967A/ja
Publication of JP2005516967A5 publication Critical patent/JP2005516967A5/ja
Withdrawn legal-status Critical Current

Links

JP2003559508A 2002-01-18 2003-01-20 β−セクレターゼインヒビター Withdrawn JP2005516967A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02001339 2002-01-18
EP02012566 2002-06-05
PCT/EP2003/000504 WO2003059346A1 (en) 2002-01-18 2003-01-20 Beta-secretase inhibitors

Publications (2)

Publication Number Publication Date
JP2005516967A JP2005516967A (ja) 2005-06-09
JP2005516967A5 true JP2005516967A5 (https=) 2006-01-05

Family

ID=26077568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003559508A Withdrawn JP2005516967A (ja) 2002-01-18 2003-01-20 β−セクレターゼインヒビター

Country Status (6)

Country Link
US (1) US20050239899A1 (https=)
EP (1) EP1467729A1 (https=)
JP (1) JP2005516967A (https=)
AU (1) AU2003205630A1 (https=)
CA (1) CA2473441A1 (https=)
WO (1) WO2003059346A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP1667983A4 (en) * 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
JP2007533743A (ja) 2004-04-20 2007-11-22 メルク エンド カムパニー インコーポレーテッド アルツハイマー病治療のためのβ−セクレターゼ阻害薬として有用な1,3,5−置換フェニル誘導体化合物
WO2006029850A1 (en) * 2004-09-14 2006-03-23 The Genetics Company, Inc. Hydrazone derivatives and their use as beta secretase inhibitors
CA2580767A1 (en) 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
JP2009513670A (ja) * 2005-10-31 2009-04-02 シェーリング コーポレイション アスパルチルプロテアーゼインヒビター
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009084034A2 (en) * 2007-12-18 2009-07-09 Glenmark Pharmaceuticals, S. A. Chromane derivatives as trpv3 modulators
MX2010011762A (es) * 2008-06-17 2011-02-03 Glenmark Pharmaceuticals Sa Derivados de cromano como moduladores del trpv3.
US8580841B2 (en) * 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
HRP20160890T1 (hr) * 2008-08-27 2016-09-23 Arena Pharmaceuticals, Inc. Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ, インコーポレイテッド (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚o-甲基轉移酶活性抑制化合物
UY35590A (es) 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
KR102479822B1 (ko) 2016-02-05 2022-12-21 인벤티스바이오 엘엘씨 선택적 에스트로겐 수용체 분해제 및 이들의 용도
SI3507291T1 (sl) 2016-09-02 2021-11-30 Cyclerion Therapeutics, Inc. Kondenzirani biciklični SGS stimulatorji
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN109745324B (zh) * 2017-11-06 2026-02-06 中国科学院上海营养与健康研究所 非经典NF-kB通路的小分子抑制剂及其应用
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN112955431A (zh) 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07309822A (ja) * 1994-05-18 1995-11-28 Asahi Chem Ind Co Ltd フェニルプロピオンアニリド誘導体
JP2000514815A (ja) * 1996-07-24 2000-11-07 ノバルティス アクチェンゲゼルシャフト 農薬組成物
US6660737B2 (en) * 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones

Similar Documents

Publication Publication Date Title
JP2005516967A5 (https=)
ES2613931T3 (es) Compuestos peptídicos para tratar el estado epiléptico refractario
RU2309953C2 (ru) Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
TW200621249A (en) Substituted amide beta secretase inhibitors
JP2006507220A5 (https=)
JP2006512417A5 (https=)
WO2012072713A2 (en) Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
RU2005103398A (ru) Производные 7,8,9,10-тетрагидро-6h-азепино-, 6,7,8,9-тетрагидропиридо-и 2,3-дигидро-2h-пирроло-[2,1-b]-хиназолинона
JP2007511504A5 (https=)
JP2004505912A5 (https=)
JP2007508360A5 (https=)
JP2006503850A5 (https=)
JP2009515887A5 (https=)
JP2003509349A5 (https=)
JP2006500394A5 (https=)
WO2005056524A3 (en) Therapeutic agents useful for treating pain
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
JP2006504738A5 (https=)
JP2004509845A5 (https=)
JP2004534064A5 (https=)
EA200501425A1 (ru) Арилвинилазациклоалкановые соединения и способы их получения и применения
ATE538784T1 (de) Verfahren zur behandlung von substanzbedingten erkrankungen
WO2002036118A3 (en) Heterocyclic derivatives useful as pharmaceutical agents
JP2006510659A5 (https=)